GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/24/2026

1. SPCX
2. META
3. ABBV
4. SPY
5. FDX
6. IBM
7. NKE
8. MU
9. ACN
10. USO

Go back to GlycoMimetics Announces Design of Phase 3 Clinical Trial for GMI-1271 in Relapsed/Refractory AML
GLYCOMIMETICS (NASDAQ: GLYC) Delayed: 0.16 --0 (-0%)
Previous Close $0.16    52 Week High $9.25 
Open $0.16    52 Week Low $3.70 
Day High $0.16    P/E N/A 
Day Low $0.16    EPS $0.00 
Volume 5,755